EDGAR·FLOW

Most material SEC filings — September 30, 2026

50 filings analyzed. Top movers: Integer Holdings Corp, SKYWORKS SOLUTIONS, INC., NOMAD POWER SOLUTIONS, INC., Inflection Point Acquisition Corp. VIII, Outlook Therapeutics, Inc..
8-K Integer Holdings Corp
Integer Holdings received early termination of the Hart-Scott-Rodino antitrust waiting period for KKR's pending acquisition at $127 per share in cash, valuing the transaction at approximately $5.7 billion enterprise value. Stockholder vote is scheduled for October 21, 2026, with closing expected by end of 2026, subject to stockholder approval and other regulatory conditions. The deal was announced August 3, 2026 with definitive merger agreement dated August 2, 2026.
— Neutral · significance 92 · 8-K Agent
8-K SKYWORKS SOLUTIONS, INC.
Skyworks Solutions announced receipt of all necessary regulatory clearances for its previously announced cash-and-stock combination with Qorvo, Inc., with closing expected on or about October 5, 2026. The transaction was originally announced October 28, 2025, and combines two RF/analog/mixed-signal semiconductor leaders. Skyworks also confirmed pending debt exchange offers for Qorvo's outstanding 4.375% Senior Notes due 2029 and 3.375% Senior Notes due 2031, contingent on merger closing.
▲ Likely positive · significance 92 · 8-K Agent
8-K NOMAD POWER SOLUTIONS, INC.
Nomad Power Solutions issued a $6.57M secured promissory note to Streeterville Capital, LLC on September 28, 2026, with a $6M purchase price (after $540K OID and $30K transaction fees). The note carries 9% annual interest, matures in 12 months, and is secured by all company assets plus guaranties from three subsidiaries (Lixte Biotech, Nomad Transportable Power, Liora Tech Europe). Terms include mandatory prepayments of 25% of future fundraising proceeds, lender redemption rights of up to $800K/month starting month 6, and extensive trigger events (including stock delistings, covenant breaches, reverse splits) that can accelerate the debt.
▼ Likely negative · significance 92 · 8-K Agent
8-K Inflection Point Acquisition Corp. VIII
Inflection Point Acquisition Corp. VIII completed a 28.75M-unit IPO on August 31, 2026 (including 3.75M overallotment units), raising approximately $718.75M. Starting October 5, 2026, unit holders may elect to separately trade Class A shares (IPHX) and warrants (IPHXW) on Nasdaq; unseparated units continue trading as IPHXU. The SPAC seeks a business combination in disruptive growth sectors in North America or Europe.
— Neutral · significance 92 · 8-K Agent
8-K Outlook Therapeutics, Inc.
Outlook Therapeutics (market cap ~$26.9M) received a Notice of Delisting or Failure to Satisfy Continued Listing standards on September 25, 2026, filed via 8-K on September 30, 2026. The filing does not specify which exchange issued the notice, the specific rule(s) violated, cure timelines, or remedial actions. No financial impact, counterparties, or dollar amounts are detailed in the filing header.
▼ Likely negative · significance 88 · 8-K Agent
8-K Marygold Companies, Inc.
On September 25, 2026, Marygold Companies entered into a definitive merger agreement with funds managed by Madison Dearborn Partners to acquire all outstanding shares at $2.00 per share. The Board's Special Committee and full Board unanimously approved the transaction, and holders of approximately 75% of voting shares delivered written consent approving the Merger Agreement. The Company conducted an extensive process prior to the deal and received several alternative proposals.
— Neutral · significance 87 · 8-K Agent
8-K KLX Energy Services Holdings, Inc.
KLX Energy Services Holdings, Inc. (market cap ~$29M) executed an amended and restated indenture dated September 29, 2026, for its Senior Secured Floating Rate Cash/PIK Notes due 2030. The amendment consolidates $232.16M in principal amount of previously issued notes and provides for PIK (payment-in-kind) interest election, allowing holders to receive interest as additional notes or principal increases. Key terms remain substantially similar, with floating rate interest (Term SOFR or Alternate Base Rate) and 8.5% applicable margin at restatement effective date. The amendment also incorporates a rights offering backstop agreement whereby specified holders agreed to equitize a portion of their holdings—a critical recapitalization event for the distressed issuer.
▼ Likely negative · significance 82 · 8-K Agent
8-K PEOPLES BANCORP INC
Peoples Bancorp Inc. (Ohio, ~$1.0B market cap) agreed to acquire Capital Bancorp Inc. (Maryland) in an all-stock merger effective September 29, 2026. Capital shareholders receive 1.11 Peoples Common Stock per share (the Exchange Ratio). The merger requires shareholder approval from both companies and regulatory approval from FRB, OCC, FDIC, ODFI, MDOFR, and others. Closing expected in first business day of month following final regulatory approval.
▲ Likely positive · significance 78 · 8-K Agent
8-K POWERCOMPUTE, INC.
PowerCompute's subsidiary fully repaid and terminated its Arch Lending Bitcoin-backed credit facility on September 24, 2026, satisfying ~$22.45M in principal, interest, and fees by allowing Arch to sell ~267.3 of 307 pledged Bitcoin. Total secured debt fell 94% from $19.4M (June 30, 2026) to $1.25M; ~39.6 BTC (valued ~$3.3M) returned to company; no Bitcoin remains pledged. Company now holds ~62 BTC ($5.2M at $84.5k/BTC as of Sept 25) and plans Mississippi/Oklahoma expansions targeting 25% hash rate increase to ~964 PH/s.
▲ Likely positive · significance 78 · 8-K Agent
8-K Leslie's, Inc.
Leslie's, Inc. executed a Restructuring Support Agreement (RSA) dated September 30, 2026, with consenting term loan lenders holding ≥66.67% of prepetition term loan claims. The restructuring contemplates: (1) a $90M DIP term loan facility (with $75M converting to new term loans, remainder to equity); (2) a $225M DIP ABL facility; (3) $60M equity financing at a discounted plan equity value; (4) prepetition term loan holders receiving 10% of new common equity; and (5) a $500,000 general unsecured creditor pool. Company will file Chapter 11 in Southern District of Texas, targeting confirmation within ~100 days. DIP and equity backstop premiums (7% and 7.5% respectively) are payable by the company.
▼ Likely negative · significance 78 · 8-K Agent
8-K MICRON TECHNOLOGY INC
Micron reported fiscal 2026 revenue of $133.19B (vs. $37.38B prior year) and net income of $84.97B ($74.33 EPS), with Q4-26 revenue $54.23B and net income $37.70B. The company guided FQ1-27 revenue at $61.5B ± $1.5B with diluted EPS of $37.84 ± $1.00 GAAP ($38.15 ± $1.00 non-GAAP). Cash position strengthened to $73.48B; operating cash flow reached $89.68B for the year. All business units showed strong margins (83–90% gross margin) driven by AI-driven demand.
▲ Likely positive · significance 78 · 8-K Agent
8-K Rank One Computing Corp
Rank One Computing Corporation (Nasdaq: ROC) was awarded an 8-year contract by the U.S. Department of Justice on September 14, 2026, valued at $64.3 million total ($7.4M base period committed for 09/22/2026–09/21/2027, with seven optional 1-year periods worth $56.9M if exercised at DOJ's discretion). ROC Evidence will develop and support DERP (Digital Evidence Review Platform) for ingestion, review, analysis, and production of e-discovery content including cell phone and social media data for federal prosecutions. The contract includes time-and-materials, firm-fixed-price licensing, and travel cost components.
▲ Likely positive · significance 78 · 8-K Agent
4 Kodiak Sciences Inc.
Director BAKER BROS. ADVISORS LP (KOD) bought 808K shares (~$58.6M) on the open market (4.1% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
4 Kodiak Sciences Inc.
Director BAKER BROS. ADVISORS LP (KOD) bought 418K shares (~$35.0M) on the open market (2.1% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
4 Kodiak Sciences Inc.
Director BAKER BROS. ADVISORS LP (KOD) bought 716K shares (~$63.4M) on the open market (3.4% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
4 Corebridge Financial, Inc.
10% owner NIPPON LIFE INSURANCE CO (CRBG) bought 806K shares (~$27.5M) on the open market (0.6% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
8-K Zone Frontier Inc.
Zone Frontier's subsidiary entered a 30-year ground lease (with two 10-year extensions) covering 4,077 acres in Potter County, Texas. The lease allows designation of 200–800 acres for data center facilities (potential 500+ MW capacity) and ≥1,800 acres for solar/battery infrastructure. Base rent commences only upon construction start on each area; the agreement includes a purchase option for the data center site and long-term water supply agreement. No specific dollar amounts or lease payment terms are disclosed.
▲ Likely positive · significance 78 · 8-K Agent
8-K MacKenzie Realty Capital, Inc.
MacKenzie Realty Capital reported FY2026 revenues of $20.01M (down 9% YoY) and net loss of $14.13M (improved 41% from $23.97M prior year). The Board suspended its Preferred Share Repurchase Program and engaged Maxim Group LLC to explore strategic alternatives including reverse takeovers, citing that the repurchase program created selling pressure on common stock that would complicate M&A negotiations. No specific dollar amounts, share counts, or timeline for strategic transactions were disclosed.
— Neutral · significance 78 · 8-K Agent
4 ADARx Pharmaceuticals, Inc.
Director ORBIMED ADVISORS LLC (ADRX) bought 24.2M shares (~$16.1M) on the open market (98% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
S-1 GEN Restaurant Group, Inc.
On September 29, 2026, GEN Restaurant Group signed a Common Stock Purchase Agreement with Roth Principal Investments, LLC, granting the right to sell up to $25 million of Class A Common Stock over 36 months at VWAP-based prices (3–5% discount). Roth Principal will resell up to 15 million registered shares. Company receives no proceeds from Roth's resales but will receive up to ~$24M net proceeds from direct sales to Roth (after ~$1M in fees: $500K commitment fee, $150K initial legal/QIU, ~$350K ongoing legal). Shares issued are capped at 6.78M (19.99% of outstanding) unless stockholder approval or Base Price of $1.78 is met; Roth capped at 4.99% beneficial ownership.
▼ Likely negative · significance 78 · Registration Agent
4 ADARx Pharmaceuticals, Inc.
Director GORDON CARL L (ADRX) bought 24.2M shares (~$16.1M) on the open market (98% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
4 LENNAR CORP /NEW/
10% owner BERKSHIRE HATHAWAY INC (LEN) bought 660K shares (~$53.9M) on the open market (54% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
4 GROUP 1 AUTOMOTIVE INC
10% owner Conifer Management, L.L.C. (GPI) bought 274K shares (~$66.3M) on the open market (13% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
8-K CalciMedica, Inc.
CalciMedica, Inc. (Delaware corporation) filed a prospectus supplement on September 30, 2026, registering up to 25,000,000 shares of common stock (par value $0.0001/share) for sale under an At the Market (ATM) Offering Agreement with H.C. Wainwright Co., LLC dated August 11, 2023. The aggregate offering price is up to $25,000,000. This is a standard legal opinion letter confirming the shares will be validly issued, fully paid, and nonassessable under Delaware law.
— Neutral · significance 76 · 8-K Agent
8-K Liquidia Corp
U.S. District Court for Delaware found that claims 1 and 14 of United Therapeutics' U.S. Patent No. 11,826,327 are valid and infringed by Liquidia's YUTREPIA (treprostinil) inhalation powder; four other asserted claims were ruled invalid. Parties must submit proposed remedies within one week. UTHR is seeking injunctive relief that could restrict or block YUTREPIA's market availability, though Liquidia plans to appeal and remove the PH-ILD indication from the label.
▼ Likely negative · significance 76 · 8-K Agent
8-K CAL-MAINE FOODS INC
Cal-Maine Foods reported Q1 FY2027 (ended August 29, 2026) net sales of $539.6M vs. $922.6M prior year (−41.5%), with net loss of $58.6M vs. net income of $199.3M (−$257.9M swing). Conventional Shell Eggs segment revenue fell 59.5% due to 59.3% price decline from industry oversupply post-flock repopulation; segment loss was $71.0M vs. $168.2M income prior year. Specialty Shell Eggs and Prepared Foods now represent 54.1% of sales (up from 37.1%). Company acquired Eggland's Best franchise in Northeast and continues capacity expansion targeting 60%+ growth in Prepared Foods by H1 FY2028. Repurchased 66,601 shares for $5.0M in Q1; suspended dividend until cumulative loss of $94.5M is recovered.
▼ Likely negative · significance 72 · 8-K Agent
8-K/A Zedge, Inc.
Zedge completed a $7.7M private placement generating gross proceeds of $7.675M. Vice Chairman Howard Jonas (via Chartwell Holding LLC) invested $6.5M for 2,218,430 shares of Class B common stock and warrants to purchase 1,996,587 shares at $3.22/share exercise price. Board member Elliott Gibber and another shareholder also participated. Total issuance: 2,616,447 shares and warrants for 2,354,803 shares. Proceeds will fund DataSeeds.AI expansion.
▲ Likely positive · significance 72 · 8-K Agent
8-K Capital Bancorp Inc
Peoples Bancorp Inc. (Ohio) agreed to acquire Capital Bancorp Inc. (Maryland) in an all-stock merger dated September 29, 2026. Capital shareholders will receive 1.11 shares of Peoples Common Stock per Capital share (Exchange Ratio). Capital Bank will merge into Peoples Bank. No specific dollar amount or stock counts provided in the filing excerpt; Capital Bancorp's market value is ~$374.6M. Deal is structured as a tax-free reorganization under IRC Section 368(a)(1)(A).
— Neutral · significance 72 · 8-K Agent
8-K Connect Biopharma Holdings Ltd
Connect reported topline results from the Phase 2 Seabreeze STAT COPD trial (159 participants, 1:1 randomization) showing rademikibart 600 mg subcutaneous significantly reduced treatment failure by 81% (p=0.0122), new moderate-to-severe exacerbations by 85% (p=0.030), and hospital/ED returns by 100% (p=0.0137) through Week 4. The drug showed a favorable safety profile comparable to placebo. Company plans FDA engagement for Phase 3 development in acute and chronic COPD indications.
▲ Likely positive · significance 72 · 8-K Agent
8-K Professional Diversity Network, Inc.
Professional Diversity Network, Inc. (NASDAQ: IPDN) received written confirmation on September 28, 2026 from Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per share. The company had been notified on June 5, 2026 that its stock had closed below $1.00 for 30 consecutive business days. Following a reverse stock split, the closing bid price remained at or above $1.00 from September 14–25, 2026, resolving the compliance matter.
▲ Likely positive · significance 72 · 8-K Agent
8-K Rafael Holdings, Inc.
Rafael Holdings announced September 30, 2026 topline results from its pivotal Phase 3 TransportNPC study of Trappsol Cyclo in 94 Niemann-Pick Disease Type C patients (63 drug, 31 placebo). The primary endpoint—change in 4DNPCSS at Week 96—did not achieve statistical significance (p=0.19), showing 64% slowing of disease progression. However, a prespecified subgroup analysis of 78 patients (83% of study population) on background miglustat and/or leucine therapy showed statistical significance (p=0.046) with 71% disease progression slowing. Company remains on track for NDA submission in Q4 2026 pending FDA review.
▼ Likely negative · significance 72 · 8-K Agent
8-K AEON Biopharma, Inc.
AEON received FDA feedback on ABP-450 (botulinum toxin biosimilar to BOTOX) development. The FDA agreed in principle to a two-stage comparative pharmacodynamic (CMAP) study design and indicated previously completed Daewoong studies in blepharospasm, upper limb spasticity, and cosmetic indications may be submitted as supportive evidence with scientific bridging. AEON plans to submit an IND for the CMAP study in Q4 2026 and intends to avoid a standalone comparative efficacy study by leveraging analytical, pharmacodynamic, and existing comparative human evidence; the company expects to return to the FDA in 2027 with an integrated evidence package.
▲ Likely positive · significance 72 · 8-K Agent
8-K Celcuity Inc.
Celcuity announced on September 30, 2026, that REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer without PIK3CA mutation following progression after endocrine therapy. FDA approved the drug on July 14, 2026, for use in combination with fulvestrant alone (doublet) or with palbociclib plus fulvestrant (triplet). In the Phase 3 VIKTORIA-1 trial's PIK3CA wild-type cohort, REVTORPYK triplet and doublet reduced risk of disease progression or death by 76% and 67% respectively versus fulvestrant. The company has launched REVTORPYK Support Services for patient access and reimbursement assistance.
▲ Likely positive · significance 72 · 8-K Agent
8-K ACM Research, Inc.
ACM Research's Shanghai subsidiary reported total backlog of RMB 17.1 billion (~$2.5 billion USD) as of September 29, 2026, representing an 88.2% year-over-year increase. The backlog includes both shipped tools not yet revenue-recognized under Chinese GAAP and future-shipment orders. Full financial results for Q3 2026 will be reported in early November 2026.
▲ Likely positive · significance 72 · 8-K Agent
8-K Trump Media & Technology Group Corp.
Trump Media Technology Group (TMTG) has issued an amended and restated $200M unsecured convertible promissory note to TAE Technologies, Inc., dated September 30, 2026, replacing a prior note from December 18, 2025. The note bears 7% annual interest (paid-in-kind), matures in two years, and includes an option for an additional $100M drawdown. TAE will become a publicly traded company upon merger close, with TMTG and TAE shareholders each owning ~50% on a fully diluted basis. TMTG filed a Form S-4 registration statement on September 30, 2026 to advance the all-stock combination announced December 18, 2025. The note grants TMTG pre-conversion voting rights on 25% of conversion value and converts to senior equity at original issuance price upon qualified financing or merger termination.
▲ Likely positive · significance 72 · 8-K Agent
8-K MATTEL INC /DE/
Roger Lynch, current board member and Independent Lead Director, appointed Chairman effective October 2, 2026 and CEO effective on or before November 2, 2026, succeeding Ynon Kreiz. Lynch receives $2.3M annual base pay, $10.6M make-whole signing bonus (repayable if he leaves before Dec 31, 2027), $6M make-whole RSU award (repayable if early termination), $6M inducement PSU award (3-year cliff vest at 55th percentile TSR vs S&P 500), $10M 2026 annual LTI grant (60% PSU / 40% RSU), 200% target MIP bonus, $985K relocation allowance, and standard executive benefits. Kreiz departs to take senior role at another public company after 8 years leading Mattel's transformation into IP-driven entertainment company.
— Neutral · significance 72 · 8-K Agent
8-K Silexion Therapeutics Corp
Silexion dosed the first patient in its global Phase 2/3 clinical trial of SIL204 on September 30, 2026, at Tel Aviv Sourasky Medical Center in Israel. The trial is a randomized, controlled study enrolling approximately 18 patients in a safety run-in cohort followed by ~166 patients in a randomized expansion cohort, evaluating SIL204 combined with standard chemotherapy versus chemotherapy alone in locally advanced pancreatic cancer patients with KRAS mutations. SIL204 uses a novel dual-route delivery combining EUS-guided intratumoral injection and subcutaneous dosing.
▲ Likely positive · significance 72 · 8-K Agent
8-K Trio Petroleum Corp
Trio Petroleum's Canadian subsidiary acquired 24 oil wells (4 producing, 20 shut-in) from Marlin Resources Ltd. for CAD$800,000 cash plus transfer of a water disposal asset, effective September 25, 2026. The deal includes 37 BOPD current production, a planned CAD$1.2M Cummings multilateral well, and CAD$425K workover program targeting significant production growth.
▲ Likely positive · significance 72 · 8-K Agent
8-K Q32 Bio Inc.
Q32 Bio reported Part B SIGNAL-AA trial results for bempikibart in 33 patients with severe/very severe alopecia areata: 40% achieved SALT-20 response (primary endpoint, mean 35.3% SALT score reduction at Week 36), with 44% maintaining SALT-20 during 16-week off-drug follow-up. Safety was favorable with no serious/Grade 3+ adverse events; most common event was injection site reaction (36.3%, mild, self-resolving). Company plans to initiate registration-directed program in H1 2027 pending regulatory meetings in H2 2026.
▲ Likely positive · significance 72 · 8-K Agent
8-K PROGRESS SOFTWARE CORP /MA
Progress Software completed acquisition of Domo's AI and Data Platform business for $400M cash on September 22, 2026. Q3 2026 revenue was $246M (down 2% YoY); ARR reached $873M (up 1% YoY constant currency). Non-GAAP operating margin 43%, non-GAAP EPS $1.69 (up 13% YoY). Company raised FY2026 revenue guidance to $1,044M–$1,052M (from $990M–$1,002M) and non-GAAP EPS to $6.15–$6.23 (from $6.09–$6.21). Post-acquisition pro forma net leverage approximately 2.9x; Domo adds ~$21M incremental FY2027 interest expense.
▲ Likely positive · significance 72 · 8-K Agent
8-K REGENERON PHARMACEUTICALS, INC.
CEO Leonard Schleifer received 2.7M PSUs and Chief Scientific Officer George Yancopoulos received 2.9M PSUs, both granted September 24, 2026. Awards span 10 years (2026–2035) with three performance tracks: (1) activity-based PSUs for FDA filings (10,000 per filing) and approvals (15,000 per approval); (2) revenue-based PSUs scaled to $10B–$30B in new product sales (0–1.8M PSUs annually); (3) relative TSR modifier (±20% adjustment vs. NASDAQ Biotech Index). No additional equity awards permitted either executive through December 31, 2035. Shares subject to 80/20 holdback (20% retained until 2036) and mandatory holding period through certification date.
— Neutral · significance 72 · 8-K Agent
8-K AIB Data Centers Inc.
AIB Data Centers signed a Master Colocation Services Agreement with Nebius Inc. (backed by $50B+ parent Nebius Group N.V.) for 50 MW of critical IT capacity at CLT1 in South Carolina over a 12-year initial term with two optional 5-year renewals. Contract value is approximately $1.32B ($2.2M/MW/yr implied rate). Nebius will prepay initial development costs and provide a guaranty. Electric service agreement (65 MW utility power) was signed in May 2026; ESA service commences October 1, 2026, with data halls delivered ~months 10 and 14.
▲ Likely positive · significance 72 · 8-K Agent
8-K Childrens Place, Inc.
On September 24, 2026, Children's Place, Inc. drew $25 million from Mithaq Capital SPC under an unsecured promissory note (the Fourth Mithaq Subordinated Note), following a $15 million draw on July 1, 2026 (Third Mithaq Subordinated Note). Total commitment from Mithaq is $40 million. The facility matures April 16, 2031; bears interest at Term SOFR + 9.00% (monthly, deferrable); is fully subordinated to senior secured debt; and is non-dilutive, as proceeds fund working capital and repay ABL revolving borrowings.
— Neutral · significance 72 · 8-K Agent
8-K/A Global Net Lease, Inc.
On August 12, 2026, Global Net Lease (GNL) completed acquisition of Modiv Industrial (NYSE: MDV) for estimated purchase price of $543.982M: $227.5M in equity consideration (20.4M GNL shares at $8.99/share issued at 1.975:1 ratio plus $44.2M OP units to Modiv unitholders) plus $316.5M cash to repay Modiv's $23.7M mortgage, $250M term loan, and $42.3M preferred stock, funded via GNL's revolving credit facility. Pro forma combined balance sheet shows total assets of $4.63B; combined H1 2026 revenue $244.7M with net loss of $(24.0)M attributable to common stockholders; full-year 2025 pro forma revenue $539.0M with net loss $(183.4)M. GNL share count increased from 212.7M to 233.1M weighted average (H1 2026). Final purchase price allocation remains preliminary pending valuation work.
▼ Likely negative · significance 72 · 8-K Agent
8-K Health In Tech, Inc.
Health In Tech announced HitRix, an AI-powered platform for large-group self-funded health insurance workflows, launching across its 933-partner distribution network (19.9% YoY growth as of June 30, 2026). The company revised 2026 full-year revenue guidance to approximately $33 million, roughly flat versus 2025, citing timing of HitRix commercialization, a Three-Year Rate Stabilization Program, and carrier capacity expansion. Management expects these initiatives to contribute materially beginning in 2027.
— Neutral · significance 72 · 8-K Agent
8-K Madison Square Garden Sports Corp.
MSGC distributes 100% of Spinco (Rangers business) to shareholders on 1:1 basis for Class A and Class B shares. Distribution Agreement dated September 30, 2026 governs the separation of the NBA Knicks and NHL Rangers franchises. Spinco becomes independent public company; MSG Sports retains other businesses. Tax-free distribution contemplated under IRC §355/368(a)(1)(D). No specific dollar amounts or financial terms disclosed in agreement text.
— Neutral · significance 72 · 8-K Agent
8-K Tevogen Inc.
Tevogen Inc. (Nasdaq: TVGN) received written notice from Nasdaq on September 29, 2026, confirming regained compliance with the $50 million minimum market value of listed securities requirement under Listing Rule 5450(B)(2)(A). Combined with prior notice on September 9, 2026, confirming compliance with minimum market value of publicly held shares (Rules 5450(B)(2)(C) and 5450(B)(3)(C)), both Nasdaq delisting-risk compliance matters are now closed.
▲ Likely positive · significance 72 · 8-K Agent
8-K Immix Biopharma, Inc.
Immix Biopharma priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share on September 29, 2026, generating gross proceeds of approximately $125 million. J.P. Morgan Securities LLC acted as sole book-running manager. The company intends to use net proceeds for NXC-201 development, working capital, and general corporate purposes. Closing was expected September 30, 2026.
▲ Likely positive · significance 72 · 8-K Agent
8-K Newbury Street II Acquisition Corp
Newbury Street II Acquisition Corp (Nasdaq: NTWO) and FORT Robotics, Inc. announced confidential submission of a draft Form S-4 registration statement on September 30, 2026, advancing their proposed merger. The transaction values FORT at ~$556.6M enterprise value ($500M pre-money equity), with expected gross proceeds of ~$201M (assuming no SPAC redemptions) and net cash to combined company of ~$182M. FORT is backed by Tiger Global, Mark Cuban Companies, and others; posted 62% YoY revenue growth in 2025 with 66% gross margin; and has deployed 19,500+ units across 600+ customers including Google DeepMind, Zoox, and DoorDash. Closing expected Q4 2026 or Q1 2027.
▲ Likely positive · significance 72 · 8-K Agent
SCHEDULE 13D Silvercrest Asset Management Group Inc.
Equinox Partners Investment Management LLC, Equinox Partners L.P., and Sean M. Fieler (reporting persons) jointly filed a Schedule 13D on September 30, 2026, disclosing open-market purchases of approximately 575,627 shares of Silvercrest common stock during the 60-day period ending September 30, 2026. Purchases ranged from $9.17 to $10.54 per share, accumulating at a total cost of approximately $5.7M. The filing indicates a significant equity stake acquisition but does not disclose the current aggregate ownership percentage or intent.
— Neutral · significance 72 · Ownership Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.